- Company
- Varying sales of Korean subsidiaries of multinational pharma
- by Son, Hyung Min Apr 15, 2025 05:54am
- The 2024 sales performance of multinational pharmaceutical companies' subsidiaries in South Korea varied. Pfizer Korea, MSD Korea, and Gilead Sciences Korea experienced a significant drop in sales due to the impact of COVID-19 becoming endemic. Novo Nordisk saw substantial external growth following the launch of new drugs for diabetes and obesit
- Company
- ImmuneOncia seeks opportunity in the PD-1 market
- by Cha, Jihyun Apr 14, 2025 05:57am
- “PD-(L)1 antibodies are the backbone of immuno-oncology drugs. In the future, immuno-oncology developers will be divided into companies with PD-(L)1 drugs and those without. ImmuneOncia will commercialize its own PD-(L)1 drug and continue to grow based on this.” Heung-Tae Kim, CEO of ImmuneOncia, said so about the company's growth strategy
- Company
- Alesion 1% may be prescribed in general hospitals in KOR
- by Eo, Yun-Ho Apr 14, 2025 05:56am
- ‘Alesion LX 1% Eye Drop,’ an antiallergic drug for allergic conjunctivitis, may now be prescribed at general hospitals in Korea. According to industry sources, Santen’s Alesion LX 1% Eye Drops, Korea's first eye drop that contains 1 mg epinastine hydrochloride, have passed the drug committee (DC) reviews of medical institutions in Kore
- Company
- KPTA and Pharmexcil to sign MOU to expand Korea-India trade
- by Kim, Jin-Gu Apr 14, 2025 05:56am
- The Korea Pharmaceutical Traders Association announced on the 10th that it has agreed to mutually cooperate with the Pharmaceutical Export Promotion Council of India (Pharmexcil), which participated in the 'CPHI JAPAN 2025' exhibition held on the 10th, to expand pharmaceutical trade and promote the development of the health industry in both
- Company
- "Jardiance's role in total management of CRM: next 10 years"
- by Whang, byung-woo Apr 11, 2025 06:01am
- Boehringer Ingelheim Korea's recent history aligns with the growth of its SGLT-2 inhibitor Jardiance (empagliflozin). Jardiance began as a treatment for type 2 diabetes and demonstrated benefits for cardiovascular-renal-metabolism (CRM), being the first among SGLT2 inhibitors, achieving a total management milestone. As the Phase 3 EMP
- Company
- Reimbursement negotiation on track for Bimzelx
- by Whang, byung-woo Apr 11, 2025 06:01am
- As the reimbursement negotiations process for Bimzelx (bimekizumab), a new psoriasis treatment, is picking up speed, the drug is soon expected to enter the market in earnest. According to industry sources on the 10th, UCB Korea is in drug price negotiations for Bimzelx's entry into the reimbursement list. After receiving approval for B
- Company
- Reimbursement listing of Handok’s Doptelet near
- by Son, Hyung Min Apr 11, 2025 06:00am
- Doptelet, Handok’s newly introduced drug, is close to being listed for insurance reimbursement in Korea. According to industry sources, Handok has accepted the conditions presented by the Drug Reimbursement Evaluation Committee of the Health Insurance Review and Assessment Service for Doptelet (avatrombopag), a treatment for immune throm
- Company
- Biosimilars to Prolia compete for the market worth KRW 170B
- by Whang, byung-woo Apr 10, 2025 05:57am
- As biosimilars have been introduced following the patent expiration of the osteoporosis treatment, 'Prolia (denosumab),' competition in the market is expected to heat up. As biosimilars from Celltrion and Samsung Bioepis, distributed by Daewoong and Hanmi, respectively, become distributed, the original drug producer, Chong Kun Dang, and the b
- Company
- Yuhan "Immunotherapy candidate, Phase 1/2 IND approved"
- by Kim, Jin-Gu Apr 10, 2025 05:57am
- Yuhan announced on April 7 that it received approval from the Ministry of Food and Drug Safety (MFDS) for its investigational new drug (IND) application to initiate Phase ½ trial of 'YH32364,' a novel immunotherapy for cancer under development. According to Yuhan, YH32364 is a bispecific antibody that simultaneously targets epidermal gro
- Company
- Dupixent aims to meet unmet needs in COPD
- by Whang, byung-woo Apr 10, 2025 05:56am
- Dupixent (dupilumab), which is leading the atopic dermatitis market, is seeking to enter the market as Korea's first chronic obstructive pulmonary disease (COPD) targeted biologic drug. The company wants to open a new paradigm in the treatment of COPD, which has a high unmet need, based on Dupixent’s mechanism that targets interleukin (IL)-4
